Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Neuropharmacology|May 4, 2020
Tau immunotherapies: Lessons learned, current status and future considerationsL A Sandusky-Beltran, E M SigurdssonBiochemical Society Transactions|August 28, 2002
Therapeutics in Alzheimer's and prion diseasesT Wisniewski, D R Brown, E M SigurdssonCurrent Alzheimer Research|June 18, 2011
Tau as a therapeutic target for Alzheimer's diseaseA Boutajangout, E M Sigurdsson, P K KrishnamurthyMethods in Molecular Medicine|March 5, 2011
Conformation as therapeutic target in the prionoses and other neurodegenerative conditionsT Wisniewski, E M Sigurdsson, P Aucouturier, et al.Journal of Neuropathology and Experimental Neurology|April 1, 2000
In vivo reversal of amyloid-beta lesions in rat brainE M Sigurdsson, B Permanne, C Soto, et al.The American Journal of Pathology|August 4, 2001
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic miceE M Sigurdsson, H Scholtzova, P D Mehta, et al.Behavioural Brain Research|December 14, 1995
beta-Amyloid 25-35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effectsE M Sigurdsson, M J Hejna, J M Lee, et al.Neurobiology of Aging|February 14, 1998
Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effectsE M Sigurdsson, J M Lee, X W Dong, et al.Neurobiology of Aging|November 1, 1996
Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 ratsE M Sigurdsson, S A Lorens, M J Hejna, et al.Nature Medicine|July 14, 1998
Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapyC Soto, E M Sigurdsson, L Morelli, et al.Pageof 2